A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

Gynecologic Oncology

Volumn 110, Issue 3 SUPPL.1, 2008, Pages

  Jenkins, David ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adenocarcinoma; AS04 adjuvant; Cervical cancer; Cross protection; Mass vaccination

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; AS04 ADJUVANT; PHOSPHORYL LIPID A; WART VIRUS VACCINE;

CANCER PREVENTION; CARCINOGENICITY; CLINICAL TRIAL; DRUG FORMULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIROLOGY;

CANCER VACCINES; ENDPOINT DETERMINATION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 49549104181     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.06.027     Document Type: Review

References (40)

1. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Humanpapillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 3 (2007) 621-632
2. Muñoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjosé S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 2 (2004) 278-285
3. Franceschi S., and Clifford G.M. Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97 12 (2005) 938-939
4. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97 14 (2005) 1066-1071
5. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 14 (2005) 1072-1079
6. Castellsague X., Diaz M., de Sanjosé S., Muñoz N., Herrero R., Franceschi S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 5 (2006) 303-315
7. Clifford G., and Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int. J. Cancer 122 7 (2008) 1684-1685
8. de Sanjosé S., Quint W., Klaustemeier J., Lloveras B., Brunsveld J.P., Font R., et al. HPV type distribution in invasive cervical cancer: the worldwide perspective. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3-9 (2007)
9. Curado M.P., Edwards B., Shin H.R., Storm H., Ferlay J., Heanue M., et al. Cancer incidence in five continents, Vol. IX: endocervical adenocarcinoma. IARC Sci. Publ. No 160 (2007)
10. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
11. Herbert A., Singh N., and Smith J.A. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology 12 1 (2001) 26-36
12. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
13. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
14. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
15. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
16. Kjaer S., Hogdall E., Frederiksen K., Munk C., Van den Brule A., Svare E., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66 21 (2006) 10630-10636
17. Clifford G., Franceschi S., Diaz M., Muñoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3 (2006) S26-S34
18. World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. WHO, Geneva, Oct 23-27, 2007. http://www.who.int/biologicals/publications/trs/areas/vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf.
19. Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C., et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J. Clin. Pathol. 57 1 (2004) 68-72
20. Mendez F., Muñoz N., Posso H., Molano M., Moreno V., van den Brule A.J., et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 192 7 (2005) 1158-1165
21. Paavonen J., Jenkins D., Bosch X., Doorbar J., Quint W., Dubin G., et al. Multiple oncogenic HPV infection and the development of incident CIN2+ lesions in a Phase III trial of a HPV-16/18 L1 VLP vaccine adjuvanted with AS04 in a broad population of young women. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3-9 (2007)
22. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Atlanta, Georgia, Oct 24-25, 2007. http://www.cdc.gov/vaccines/recs/ACIP/downloads/min-oct07.pdf.
23. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (2007) 813-819
24. Koshiol J, Poole C, Chu H, Pimenta JM, Lindsay L, Jenkins D, et al., The authors respond to "HPV Persistence and Cervical Cancer Screening". Am J Epidemiol 2008;in press. Advance Access published on May 15, 2008. doi:10.1093/aje/kwn129.
25. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS, Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol 2008;in press. Advance Access published on May 15, 2008. doi:10.1093/aje/kwn036.
26. Castle PE. Invited Commentary: Is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol 2008;in press. Advance Access published on May 15, 2008. doi:10.1093/aje/kwn037.
27. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003) 518-527
28. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37 8 (1999) 2508-2517
29. Melchers W.J., Bakkers J.M., Wang J., de Wilde P.C., Boonstra H., Quint W.G., et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am. J. Pathol. 155 5 (1999) 1473-1478
30. van Doorn L.J., Quint W., Kleter B., Molijn A., Colau B., Martin M.T., et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J. Clin. Microbiol. 40 3 (2002) 979-983
31. Schlecht N.F., Trevisan A., Duarte-Franco E., Rohan T.E., Ferenczy A., Villa L.L., et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int. J. Cancer. 103 4 (2003) 519-524
32. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., and Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 76 1 (2002) 41-47
33. van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A., et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer. 98 4 (2002) 590-595
34. Meijer C.J., Snijders P.J., and Castle P.E. Clinical utility of HPV genotyping. Gynecol. Oncol. 103 1 (2006) 12-17
35. Hesselink A.T., van den Brule A.J., Groothuismink Z.M., Molano M., Berkhof J., Meijer C.J., et al. Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J. Clin. Microbiol. 43 9 (2005) 4868-4871
36. Nakagawa S., Yoshikawa H., Yasugi T., Kimura M., Kawana K., Matsumoto K., et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J. Med. Virol. 62 2 (2000) 251-258
37. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 33-34 (2006) 5937-5949
38. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet. Oncol. 6 4 (2005) 204
39. Harper D.M., Dubin G., and HPV Vaccine Study Group. Sustained HPV-16 and 18 antibody levels through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. 15th International Meeting of the European Society of Gynaecological Oncology (ESGO), Berlin, Germany, Oct 28-Nov 1 (2007)
40. Gall S.A., Teixeira J., Wheeler C.M., Naud P., Harper D.M., Franco E.L., et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. American Association for Cancer Research Annual Meeting, Los Angeles, CA, USA, Apr 14-18 (2007)